BlackRock’s Enfusion, Inc. ENFN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,435,659
| Closed | -$38.3M | – | 5637 |
|
|
2025
Q1 | $38.3M | Buy |
3,435,659
+254,477
| +8% | +$2.81M | ﹤0.01% | 2521 |
|
|
2024
Q4 | $32.8M | Sell |
3,181,182
-52,799
| -2% | -$510K | ﹤0.01% | 2725 |
|
|
2024
Q3 | $30.7M | Buy |
3,233,981
+157,238
| +5% | +$1.36M | ﹤0.01% | 2773 |
|
|
2024
Q2 | $26.2M | Buy |
3,076,743
+506,822
| +20% | +$4.64M | ﹤0.01% | 2815 |
|
|
2024
Q1 | $23.8M | Buy |
2,569,921
+58,994
| +2% | +$519K | ﹤0.01% | 2889 |
|
|
2023
Q4 | $24.4M | Buy |
2,510,927
+176,744
| +8% | +$1.65M | ﹤0.01% | 2900 |
|
|
2023
Q3 | $20.9M | Buy |
2,334,183
+742,356
| +47% | +$7.05M | ﹤0.01% | 2920 |
|
|
2023
Q2 | $17.9M | Buy |
1,591,827
+32,590
| +2% | +$289K | ﹤0.01% | 3111 |
|
|
2023
Q1 | $16.4M | Sell |
1,559,237
-71,591
| -4% | -$789K | ﹤0.01% | 3071 |
|
|
2022
Q4 | $15.8M | Buy |
1,630,828
+122,752
| +8% | +$1.38M | ﹤0.01% | 3160 |
|
|
2022
Q3 | $18.6M | Sell |
1,508,076
-76,557
| -5% | -$934K | ﹤0.01% | 3079 |
|
|
2022
Q2 | $16.2M | Buy |
1,584,633
+241,930
| +18% | +$2.67M | ﹤0.01% | 3204 |
|
|
2022
Q1 | $17.1M | Buy |
1,342,703
+49,953
| +4% | +$763K | ﹤0.01% | 3275 |
|
|
2021
Q4 | $27.1M | Buy |
+1,292,750
| New | +$26.1M | ﹤0.01% | 3090 |
|
Other funds holding ENFN
BlackRock's ENFN Position: Q2 2025 in Review
BlackRock sold out of Enfusion, Inc. (ENFN) in Q2 2025, closing a stake of 3,435,659 shares — an estimated $38.3M sold.
BlackRock first reported a position in ENFN in Q4 2021 and held it in 14 quarters. The position peaked at $38.3M in Q1 2025. 2 funds tracked by Wall St. Rank hold ENFN as of Q2 2025.
- BlackRock reported no remaining Enfusion, Inc. position as of Q2 2025 after selling out during the quarter.
- BlackRock sold 3,435,659 Enfusion, Inc. shares in Q2 2025, an estimated $38.3M.
- BlackRock first reported a position in Enfusion, Inc. in Q4 2021 and held it in 14 quarters.
- BlackRock's Enfusion, Inc. position peaked at $38.3M in Q1 2025.
- 2 funds tracked by Wall St. Rank held Enfusion, Inc. as of Q2 2025.
Based on BlackRock's 13F filing for Q2 2025, filed 12 Aug 2025.